Tissue and Metabolic Characterization of Arrhythmogenic Cardiomyopathies by Hybrid PET-MRI Imaging, Impact of the Observed Profiles on the Phenotype and on the Evolution of Cardiomyopathy

Plain-language summary

This study uses hybrid PET-MRI imaging to characterize the tissue and metabolic features of arrhythmogenic cardiomyopathies (a group of heart muscle diseases) and to explore how these profiles affect the course of the disease. It enrolls people over 16 years old who carry a pathogenic or likely pathogenic variant in related genes such as PKP2, DSG2 or DSP. It is a biocollection study without a phase and is currently recruiting participants.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Recruiting

Sponsor

Nantes University Hospital

Intervention

Biocollection

Start date

9/1/2022

Estimated completion

12/31/2026

Countries

France

Related genes

Locations

• Angers, France
• Brest, France
• Nantes, France
• Paris, France
• Rennes, France

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Male and female over 16 years old

Exclusion Criteria:

* Patients and their relatives with left ventricular or biventricular AC and carrier of a pathogenic or likely pathogenic variant in one of the following genes : PKP2, DSG2, DSC2, JUP, DSP, DES, FLNC, PLN, LMNA, TMEM43, CDH2, BAG3, RYR2, RBM20 Consent form

Exclusion Criteria :

* Sarcoidosis or known or diagnosed autoimmune disease
* History of myocardial infarction
* Patient under guardianship, curatorship or safeguard of justice